BEAM (Beam Therapeutics) Interest Expense : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Beam Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Beam Therapeutics's interest expense for the three months ended in Mar. 2025 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Beam Therapeutics's Operating Income for the three months ended in Mar. 2025 was $ -119.29 Mil. Beam Therapeutics's Interest Expense for the three months ended in Mar. 2025 was $ 0.00 Mil. GuruFocus does not calculate Beam Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Beam Therapeutics Interest Expense Historical Data

The historical data trend for Beam Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beam Therapeutics Interest Expense Chart

Beam Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.01

Beam Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Beam Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Beam Therapeutics (NAS:BEAM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Beam Therapeutics's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-119.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was $144.92 Mil.

Beam Therapeutics's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

GuruFocus does not calculate Beam Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Beam Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Beam Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beam Therapeutics Inc (NAS:BEAM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BEAM:Mexico

Address

238 Main Street, Cambridge, MA, USA, 02142

Website

https://www.beamtx.com

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Executives

Amy Simon	officer: Chief Medical Officer	BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
Christine Bellon	officer: Chief Legal Officer	BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
John M. Evans	director, officer: CEO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Giuseppe Ciaramella	officer: President & CSO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Terry-ann Burrell	officer: CFO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
John Maraganore	director	75 SIDNEY ST, CAMBRIDGE MA 02139
Graham K Cooper	director	C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Kathleen E Walsh	director	C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Stephen C Knight	director	C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Mark Fishman	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Arch Venture Partners Ix, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Keith Crandell	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631